(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano - 2How did birds survive while dinosaurs went extinct?
- 3German finance minister sees advantages of smartphones in schools
- 42023's Best 10 Cell phone Advancements You Can't Miss
- 5Soldiers seize power in Guinea-Bissau and detain the president
- Old food pyramid vs. RFK Jr.'s new food pyramid. See what's different.
- 'Crammed into a cell with vermin at New Year'
- Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure
- Exhaustive Experiences into Prudent Senior Living in the UK
- Are protests pushing Iran's Islamic regime toward a tipping point?
- Volcanic eruption led to the Black Death, new research suggests
- Historic underwater structure discovered by divers off French coast
- NASA Artemis 2 astronauts to make historic moon flyby today. Here's what to expect hour by hour (timeline)
- Real time features for Films and Programs
